The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback